CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-06-17 | BioLexis Pte Ltd. Director | Exercise or conversion | +2,181,818 | 14,039,494 | ||
| 2019-06-17 | BioLexis Pte Ltd. Director | Exercise or conversion · Warrant (Right to Buy) | −3,636,364 | 0 | ||
| 2019-04-12 | BioLexis Pte Ltd. Director | Grant or award | +3,636,364 | $2.75 | $10.0M | 11,857,676 |
| 2019-04-12 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +3,636,364 | 3,636,364 | ||
| 2019-04-12 | BioLexis Pte Ltd. Director | Grant or award · Warrant (Right to Buy) | +3,636,364 | 3,636,364 | ||
| 2019-03-31 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,542 | 63,250 | ||
| 2019-02-01 | BioLexis Pte Ltd. Director | Grant or award | +4,288,624 | $0.93 | $4.0M | 65,770,503 |
| 2019-01-02 | BioLexis Pte Ltd. Director | Grant or award | +4,288,624 | $0.93 | $4.0M | 61,481,879 |
| 2018-12-31 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,505 | 61,708 | ||
| 2018-12-03 | BioLexis Pte Ltd. Director | Grant or award | +4,288,624 | $0.93 | $4.0M | 57,193,255 |
| 2018-11-07 | BioLexis Pte Ltd. Director | Grant or award | +8,577,248 | $0.93 | $8.0M | 52,904,631 |
| 2018-09-30 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,468 | 60,203 | ||
| 2018-09-30 | BioLexis Pte Ltd. 10% owner | Other acquisition · Series A-1 Convertible Preferred Stock | +1,648 | 60,383 |
Page 2 of 2 · 33 trades